Skip to Main Content

Paper Details

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.
Cell Rep
17
2022
Author NameAffiliation
Alexandre PuissantINSERM UMR , St Louis Hospital
Raphael ItzyksonINSERM UMR , St Louis Hospital
Julio Saez-RodriguezHeidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute for Computational Biomedicine, Germany RWTH Aachen University, Joint Research Centre for Computational Biomedicine
  • 1 - 3

Datasets

Release 1.2